利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

33 条记录 (耗时 0.029 秒)

    Growth factor compositions, preparation and use
    1.
    发明授权
    Growth factor compositions, preparation and use 失效
    生长因子组成，制备和用途

    公开(公告)号：US5434135A

    公开(公告)日：1995-07-18

    申请号：US008641

    申请日：1993-01-25

    申请人： Indu Parikh ,  Ronald Nardi ,  Tanchum Amarant ,  Antonio Guglietta

    发明人： Indu Parikh ,  Ronald Nardi ,  Tanchum Amarant ,  Antonio Guglietta

    IPC分类号： C12N15/09 ,  A61K38/00 ,  A61K38/22 ,  A61P43/00 ,  C07K1/18 ,  C07K14/37 ,  C07K14/41 ,  C07K14/485 ,  C07K14/52 ,  C12P21/02 ,  C12R1/84

    CPC分类号： C07K14/485 ,  A61K38/00

    摘要： The invention in growth factor compositions includes: a novel compound which is a separate pure nicked or pure non-nicked species of epidermal growth factor EGF1-48 or its hEGF1-47 or hEGF1-49 congener compound, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition in dosage form comprising an effective amount of the novel compound and/or the known hEGF1-53; and use thereof for treating abnormal cell growth conditions including gastrointestinal/duodenal lesions; and methods of making the pure novel hEGF species. This unique therapeutic utility is enhanced by the unexpected and heretofore unappreciated structural stability and resistance of the pure species to enzymatic degradation.

    摘要翻译： 本发明在生长因子组合物中包括：一种新型化合物，其为分离的纯切口或纯非切口的表皮生长因子EGF1-48或其hEGF1-47或hEGF1-49同源化合物或其药学上可接受的盐; 包含有效量的新化合物和/或已知的hEGF1-53的剂型药物组合物; 及其用于治疗包括胃肠/十二指肠损伤的异常细胞生长条件的用途; 以及制作纯新型hEGF物种的方法。 这种独特的治疗效用通过意想不到的和迄今为止尚未被欣赏的结构稳定性和纯物质对酶降解的抗性而增强。

    Process for preparing a rapidly dispersing solid drug dosage form
    2.
    发明授权
    Process for preparing a rapidly dispersing solid drug dosage form 有权
    制备快速分散固体药物剂型的方法

    公开(公告)号：US07939105B2

    公开(公告)日：2011-05-10

    申请号：US09443863

    申请日：1999-11-19

    申请人： Indu Parikh ,  Awadhesh K. Mishra ,  Robert Donga ,  Michael G. Vachon

    发明人： Indu Parikh ,  Awadhesh K. Mishra ,  Robert Donga ,  Michael G. Vachon

    IPC分类号： A61K9/14 ,  A61K9/16

    CPC分类号： A61K9/145 ,  A61K9/19 ,  A61K47/26

    摘要： Rapidly dispersing solid dry therapeutic dosage form comprised of a water insoluble compound existing as a nanometer or micrometer particulate solid which is surface stabilized by the presence of at least one phospholipid, the particulate solid being dispersed throughout a bulking matrix. When the dosage form is introduced into an aqueous environment the bulking matrix is substantially completely dissolves within less than 2 minutes thereby releasing the water insoluble particulate solid in an unaggregated and/or unagglomerated state. The matrix is composed of a water insoluble substance or therapeutically useful water insoluble or poorly water soluble compound, a phospholipid and optionally also at least one non-ionic, anionic, cationic or amphipathic surfactant, together with a matrix or bulking agent and if needed a release agent. The volume weighted mean particle size of the water insoluble particle is 5 micrometers or less.

    摘要翻译： 快速分散固体干燥治疗剂型，其由存在于由至少一种磷脂存在而表面稳定的纳米或微米颗粒固体的水不溶性化合物组成，颗粒状固体分散在整个填充基质中。 当将剂型引入含水环境中时，膨胀基质在少于2分钟内基本上完全溶解，由此以非聚集和/或未聚集状态释放水不溶性颗粒固体。 基质由水不溶性物质或治疗上有用的水不溶性或难溶于水的化合物，磷脂和任选地至少一种非离子阴离子阳离子或两性表面活性剂以及基质或填充剂组成，如果需要， 脱模剂。 水不溶性颗粒的体积加权平均粒径为5微米以下。

    Cyclosporin emulsions
    3.
    发明授权
    Cyclosporin emulsions 失效
    环孢菌素乳剂

    公开(公告)号：US5660858A

    公开(公告)日：1997-08-26

    申请号：US627187

    申请日：1996-04-03

    申请人： Indu Parikh ,  Awadhesh Mishra

    发明人： Indu Parikh ,  Awadhesh Mishra

    IPC分类号： A61K9/107 ,  A61K31/00 ,  A61K38/00 ,  A61K38/13 ,  A61P37/00 ,  A61P37/06 ,  A61K35/13

    CPC分类号： A61K9/1075 ,  A61K38/13 ,  Y10S514/938 ,  Y10S514/943

    摘要： This invention comprises pharmaceutical compositions consisting essentially of an oil-in-water emulsion containing a synthetic medium chain triglyceride in which is dissolved a therapeutically effective amount of a cyclosporin, phospholipid and optionally free fatty acid or a salt thereof, non-ionic surfactant, ionic surfactant, glycerol, salts, buffers, preservative, osmotic modifier and antioxidant.

    摘要翻译： 本发明包括主要由含有合成中链甘油三酯的水包油乳液组成的药物组合物，其中溶解有治疗有效量的环孢菌素，磷脂和任选的游离脂肪酸或其盐，非离子表面活性剂，离子 表面活性剂，甘油，盐，缓冲液，防腐剂，渗透调节剂和抗氧化剂。

    Mucin hypersecretion inhibitors and methods of use
    5.
    发明授权
    Mucin hypersecretion inhibitors and methods of use 有权
    粘蛋白分泌过多的抑制剂和使用方法

    公开(公告)号：US08492518B2

    公开(公告)日：2013-07-23

    申请号：US12430662

    申请日：2009-04-27

    申请人： Indu Parikh

    发明人： Indu Parikh

    IPC分类号： C07K7/06

    CPC分类号： C07K7/06 ,  A61K38/00 ,  C07K5/1008 ,  C07K5/101 ,  C07K5/1013 ,  C07K5/1016 ,  C07K5/1019 ,  C07K5/1021 ,  C07K5/1024 ,  C07K14/4703 ,  C07K14/4727

    摘要： Peptides are provided that comprise less than 24 amino acids. The peptides have an amino acid sequence selected from the group consisting of: (a) an amino acid sequence having from 4 to 6 contiguous amino acids of a reference sequence PEPTIDE 1; (b) an amino acid sequence substantially identical to the sequence defined in (a); and (c) a variant of the amino acid sequence defined in (a). Also provided is a non-myristoylated MANS peptide. Various methods of using the peptides are also provided.

    摘要翻译： 提供包含少于24个氨基酸的肽。 所述肽具有选自以下的氨基酸序列：（a）具有参考序列PEPTIDE 1的4至6个连续氨基酸的氨基酸序列; （b）与（a）中定义的序列基本相同的氨基酸序列; 和（c）（a）中定义的氨基酸序列的变体。 还提供了非肉豆蔻酰化的MANS肽。 还提供了使用多肽的各种方法。

    Cyclosporiine particles
    6.
    发明授权
    Cyclosporiine particles 有权

    公开(公告)号：US06465016B2

    公开(公告)日：2002-10-15

    申请号：US09750218

    申请日：2000-12-29

    申请人： Indu Parikh ,  Robert A. Snow

    发明人： Indu Parikh ,  Robert A. Snow

    IPC分类号： A61K914

    CPC分类号： B82Y5/00 ,  A61K9/145

    摘要： Pharmaceutical compositions containing solid cyclic oligopeptide cyclosporine microparticles are prepared by applying energy input to solid cyclic oligopeptide cyclosporine in the presence of phospholipid and one or more non-ionic, anionic or cationic second surface modifiers. The microparticles consist essentially of a solid cyclic oligopeptide cyclosporine core coated with a combination of phospholipid and at least one second surface modifier. The combination of phospholipid and second surface modifier(s) provide volume-weighted mean particle size values of solid cyclic oligopeptide cyclosporine particles that are about 50% smaller than cyclic oligopeptide cyclosporine particles produced in the presence of the phospholipid and without the presence of the second surface modifier(s) using the same energy input.

    Methods for attenuating release of inflammatory mediators and peptides useful therein
    8.
    发明授权
    Methods for attenuating release of inflammatory mediators and peptides useful therein 有权
    用于减轻其中有用的炎性介质和肽的释放的方法

    公开(公告)号：US08999915B2

    公开(公告)日：2015-04-07

    申请号：US12359892

    申请日：2009-01-26

    申请人： Indu Parikh

    发明人： Indu Parikh

    IPC分类号： A61K38/08 ,  A61K38/17 ,  A61K38/10

    CPC分类号： A61K38/16 ,  A61K38/08 ,  A61K38/10 ,  A61K38/17 ,  A61K45/06

    摘要： The present invention includes methods of inhibiting or suppressing cellular secretory processes. More specifically the present invention relates to inhibiting or reducing the release of inflammatory mediators from inflammatory cells by inhibiting the mechanism associated with the release of inflammatory mediators from granules in inflammatory cells. In this regard, the present invention discloses an intracellular signaling mechanism that illustrates several novel intracellular targets for pharmacological intervention in disorders involving secretion of inflammatory mediators from vesicles in inflammatory cells. Peptide fragments and variants thereof of MANS peptide as disclosed in the present invention are useful in such methods.

    摘要翻译： 本发明包括抑制或抑制细胞分泌过程的方法。 更具体地，本发明涉及通过抑制与炎性细胞中的颗粒释放炎症介质相关的机制来抑制或减少炎性介质从炎性细胞释放。 在这方面，本发明公开了一种细胞内信号传导机制，其说明了在炎性细胞中从囊泡分泌炎症介质的病症中的药理学干预的几种新的细胞内靶标。 如本发明所公开的MANS肽的肽片段及其变体在这些方法中是有用的。

    Process for preparing a rapidly dispersing solid drug dosage form
    10.
    发明授权
    Process for preparing a rapidly dispersing solid drug dosage form 有权
    制备快速分散固体药物剂型的方法

    公开(公告)号：US07939106B2

    公开(公告)日：2011-05-10

    申请号：US10443772

    申请日：2003-05-23

    申请人： Indu Parikh ,  Awadhesh K. Mishra ,  Robert Donga ,  Michael G. Vachon

    发明人： Indu Parikh ,  Awadhesh K. Mishra ,  Robert Donga ,  Michael G. Vachon

    IPC分类号： A61K9/14 ,  A61K9/16

    CPC分类号： A61K9/145 ,  A61K9/19 ,  A61K47/26

    摘要： Rapidly dispersing solid dry therapeutic dosage form comprised of a water insoluble compound existing as a nanometer or micrometer particulate solid which is surface stabilized by the presence of at least one phospholipid, the particulate solid being dispersed throughout a bulking matrix. When the dosage form is introduced into an aqueous environment the bulking matrix is substantially completely dissolves within less than 2 minutes thereby releasing the water insoluble particulate solid in an unaggregated and/or unagglomerated state. The matrix is composed of a water insoluble substance or therapeutically useful water insoluble or poorly water soluble compound, a phospholipid and optionally also at least one non-ionic, anionic, cationic, or amphipathic surfactant, together with a matrix or bulking agent and if needed a release agent. The volume weighted mean particle size of the water insoluble particle is 5 micrometers or less.

    摘要翻译： 快速分散固体干燥治疗剂型，其由存在于由至少一种磷脂存在而表面稳定的纳米或微米颗粒固体的水不溶性化合物组成，颗粒状固体分散在整个填充基质中。 当将剂型引入含水环境中时，膨胀基质在少于2分钟内基本上完全溶解，由此以非聚集和/或未聚集状态释放水不溶性颗粒固体。 基质由水不溶性物质或治疗上有用的水不溶性或水溶性差的化合物，磷脂和任选地至少一种非离子，阴离子，阳离子或两性表面活性剂以及基质或填充剂组成，如果需要 脱模剂。 水不溶性颗粒的体积加权平均粒径为5微米以下。